Terms ending in 2039
Every in-force patent on Theravance, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,048,692 | Methods for Treating Chronic Obstructive Pulmonary Disease In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence | |
| US 12,285,417 | Methods for Treating Chronic Obstructive Pulmonary Disease In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence | |
| US 10,836,763 | 5 to 7 Membered Heterocyclic Amides as Jak Inhibitors In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | |
| US 10,947,229 | Dimethyl Amino Azetidine Amides as Jak Inhibitors In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | |
| US 11,713,315 | 5 to 7 Membered Heterocyclic Amides as Jak Inhibitors In force · Low confidence | Theravance Biopharma R&D IP, LLC | In force | Low confidence | |
| US 12,398,135 | Dimethyl Amino Azetidine Amides as Jak Inhibitors In force · Low confidence | Theravance Biopharma R&D IP, LLC | In force | Low confidence | |
| US 11,634,419 | Dimethyl Amino Azetidine Amides as Jak Inhibitors In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence | |
| US 11,484,531 | Methods for Treating Chronic Obstructive Pulmonary Disease In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.